US FDA approves Prograf to prevent rejection of heart transplant - InternationalThe US FDA has approved Prograf (tacrolimus), a drug that suppresses the body's immune reaction, for the prevention of graft rejection in the recipients of heart transplants. Prograf capsules and Prograf for injection, the first products approved in the United States for heart transplantation in eight years, had been previously approved for the prevention of graft rejection in the recipients of liver and kidney transplants. Prograf is manufactured by Illinois-based Astellas Pharma.
PROGRAF TO
draw tacrolimus
